牛乳过敏中热杀菌植物乳杆菌 YIT 0132 (LP0132) 与口服免疫疗法的组合:随机对照试验。

IF 3 4区 医学 Q2 MICROBIOLOGY
Beneficial microbes Pub Date : 2023-03-14 Epub Date: 2023-02-23 DOI:10.3920/BM2022.0064
K Yamamoto-Hanada, M Sato, K Toyokuni, M Irahara, E Hiraide-Kotaki, N Harima-Mizusawa, H Morita, K Matsumoto, Y Ohya
{"title":"牛乳过敏中热杀菌植物乳杆菌 YIT 0132 (LP0132) 与口服免疫疗法的组合:随机对照试验。","authors":"K Yamamoto-Hanada, M Sato, K Toyokuni, M Irahara, E Hiraide-Kotaki, N Harima-Mizusawa, H Morita, K Matsumoto, Y Ohya","doi":"10.3920/BM2022.0064","DOIUrl":null,"url":null,"abstract":"<p><p>Safer and more effective cow milk (CM)-oral immunotherapy that does not induce allergic reactions has not yet been standardised. We sought to explore the efficacy and feasibility of a combination of heat-killed <i>Lactiplantibacillus plantarum</i> YIT 0132 (LP0132) and oral immunotherapy for treating IgE-mediated cow milk allergy (CMA). We conducted a 24-week, double-blind, randomised (1:1), two-arm, parallel-group, placebo-controlled, phase 2 trial of LP0132 intervention for treating IgE-mediated CMA in children aged 1-18 years (n=60) from January 29, 2018 to July 12, 2019 in Tokyo, Japan. Participants were randomly assigned to the LP0132 group receiving citrus juice fermented with LP0132 or to the control group receiving citrus juice without. Both groups received low-dose slow oral immunotherapy with CM. The primary outcome was improved tolerance to CM, proven by the CM challenge test at 24 weeks. Secondary outcomes were changes in serum biomarkers of serum-specific β-lactoglobulin-IgE (sIgE) and β-lactoglobulin-IgG4 (sIgG4). Exploratory outcomes included changes in serum cytokine levels and gut microbiota composition. A total of 61 participants were included. Finally, 31 children were assigned to the LP0132 group and 30 to the control group, respectively. After the intervention, 41.4 and 37.9% of the participants in the LP0132 and control groups, respectively, showed improved tolerance to CM. In serum biomarkers after the intervention, the sIgG4 level was significantly higher, and interleukin (IL)-5 and IL-9 were significantly lower, in the LP0132 group than in the control group. In the gut microbiome, the α-diversity and <i>Lachnospiraceae</i> increased significantly in the LP0132 group, and <i>Lachnospiraceae</i> after the intervention was significantly higher in the LP0132 group than in the control group. In conclusion, low-dose oral immunotherapy with modulating gut microbiota might be a safer and more effective approach for treating cow's milk allergy.</p>","PeriodicalId":8834,"journal":{"name":"Beneficial microbes","volume":"14 1","pages":"17-30"},"PeriodicalIF":3.0000,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combination of heat-killed <i>Lactiplantibacillus plantarum</i> YIT 0132 (LP0132) and oral immunotherapy in cow's milk allergy: a randomised controlled trial.\",\"authors\":\"K Yamamoto-Hanada, M Sato, K Toyokuni, M Irahara, E Hiraide-Kotaki, N Harima-Mizusawa, H Morita, K Matsumoto, Y Ohya\",\"doi\":\"10.3920/BM2022.0064\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Safer and more effective cow milk (CM)-oral immunotherapy that does not induce allergic reactions has not yet been standardised. We sought to explore the efficacy and feasibility of a combination of heat-killed <i>Lactiplantibacillus plantarum</i> YIT 0132 (LP0132) and oral immunotherapy for treating IgE-mediated cow milk allergy (CMA). We conducted a 24-week, double-blind, randomised (1:1), two-arm, parallel-group, placebo-controlled, phase 2 trial of LP0132 intervention for treating IgE-mediated CMA in children aged 1-18 years (n=60) from January 29, 2018 to July 12, 2019 in Tokyo, Japan. Participants were randomly assigned to the LP0132 group receiving citrus juice fermented with LP0132 or to the control group receiving citrus juice without. Both groups received low-dose slow oral immunotherapy with CM. The primary outcome was improved tolerance to CM, proven by the CM challenge test at 24 weeks. Secondary outcomes were changes in serum biomarkers of serum-specific β-lactoglobulin-IgE (sIgE) and β-lactoglobulin-IgG4 (sIgG4). Exploratory outcomes included changes in serum cytokine levels and gut microbiota composition. A total of 61 participants were included. Finally, 31 children were assigned to the LP0132 group and 30 to the control group, respectively. After the intervention, 41.4 and 37.9% of the participants in the LP0132 and control groups, respectively, showed improved tolerance to CM. In serum biomarkers after the intervention, the sIgG4 level was significantly higher, and interleukin (IL)-5 and IL-9 were significantly lower, in the LP0132 group than in the control group. In the gut microbiome, the α-diversity and <i>Lachnospiraceae</i> increased significantly in the LP0132 group, and <i>Lachnospiraceae</i> after the intervention was significantly higher in the LP0132 group than in the control group. In conclusion, low-dose oral immunotherapy with modulating gut microbiota might be a safer and more effective approach for treating cow's milk allergy.</p>\",\"PeriodicalId\":8834,\"journal\":{\"name\":\"Beneficial microbes\",\"volume\":\"14 1\",\"pages\":\"17-30\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Beneficial microbes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3920/BM2022.0064\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/2/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beneficial microbes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3920/BM2022.0064","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/2/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

更安全、更有效且不会诱发过敏反应的牛奶(CM)口服免疫疗法尚未标准化。我们试图探索热杀死的植物乳杆菌 YIT 0132 (LP0132) 与口服免疫疗法相结合治疗 IgE 介导的牛奶过敏 (CMA) 的疗效和可行性。我们于2018年1月29日至2019年7月12日在日本东京开展了一项为期24周、双盲、随机(1:1)、双臂、平行组、安慰剂对照的2期试验,研究LP0132干预治疗IgE介导的1-18岁儿童CMA(n=60)。参与者被随机分配到接受用LP0132发酵的柑橘汁的LP0132组或接受不含LP0132的柑橘汁的对照组。两组均接受低剂量缓慢口服中药免疫疗法。主要结果是对中药的耐受性得到改善,24周时的中药挑战测试证明了这一点。次要结果是血清特异性β-乳球蛋白-IgE(sIgE)和β-乳球蛋白-IgG4(sIgG4)血清生物标志物的变化。探索性结果包括血清细胞因子水平和肠道微生物群组成的变化。共有 61 名参与者被纳入其中。最后,31名儿童被分配到LP0132组,30名儿童被分配到对照组。干预后,LP0132 组和对照组分别有 41.4% 和 37.9% 的参与者对中药的耐受性有所改善。在干预后的血清生物标志物中,LP0132组的sIgG4水平明显高于对照组,白细胞介素(IL)-5和IL-9则明显低于对照组。在肠道微生物组中,LP0132组的α-多样性和Lachnospiraceae明显增加,干预后LP0132组的Lachnospiraceae明显高于对照组。总之,调节肠道微生物群的低剂量口服免疫疗法可能是治疗牛奶过敏的一种更安全、更有效的方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Combination of heat-killed Lactiplantibacillus plantarum YIT 0132 (LP0132) and oral immunotherapy in cow's milk allergy: a randomised controlled trial.

Safer and more effective cow milk (CM)-oral immunotherapy that does not induce allergic reactions has not yet been standardised. We sought to explore the efficacy and feasibility of a combination of heat-killed Lactiplantibacillus plantarum YIT 0132 (LP0132) and oral immunotherapy for treating IgE-mediated cow milk allergy (CMA). We conducted a 24-week, double-blind, randomised (1:1), two-arm, parallel-group, placebo-controlled, phase 2 trial of LP0132 intervention for treating IgE-mediated CMA in children aged 1-18 years (n=60) from January 29, 2018 to July 12, 2019 in Tokyo, Japan. Participants were randomly assigned to the LP0132 group receiving citrus juice fermented with LP0132 or to the control group receiving citrus juice without. Both groups received low-dose slow oral immunotherapy with CM. The primary outcome was improved tolerance to CM, proven by the CM challenge test at 24 weeks. Secondary outcomes were changes in serum biomarkers of serum-specific β-lactoglobulin-IgE (sIgE) and β-lactoglobulin-IgG4 (sIgG4). Exploratory outcomes included changes in serum cytokine levels and gut microbiota composition. A total of 61 participants were included. Finally, 31 children were assigned to the LP0132 group and 30 to the control group, respectively. After the intervention, 41.4 and 37.9% of the participants in the LP0132 and control groups, respectively, showed improved tolerance to CM. In serum biomarkers after the intervention, the sIgG4 level was significantly higher, and interleukin (IL)-5 and IL-9 were significantly lower, in the LP0132 group than in the control group. In the gut microbiome, the α-diversity and Lachnospiraceae increased significantly in the LP0132 group, and Lachnospiraceae after the intervention was significantly higher in the LP0132 group than in the control group. In conclusion, low-dose oral immunotherapy with modulating gut microbiota might be a safer and more effective approach for treating cow's milk allergy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Beneficial microbes
Beneficial microbes MICROBIOLOGY-NUTRITION & DIETETICS
CiteScore
7.90
自引率
1.90%
发文量
53
审稿时长
>12 weeks
期刊介绍: Beneficial Microbes is a peer-reviewed scientific journal with a specific area of focus: the promotion of the science of microbes beneficial to the health and wellbeing of man and animal. The journal contains original research papers and critical reviews in all areas dealing with beneficial microbes in both the small and large intestine, together with opinions, a calendar of forthcoming beneficial microbes-related events and book reviews. The journal takes a multidisciplinary approach and focuses on a broad spectrum of issues, including safety aspects of pro- & prebiotics, regulatory aspects, mechanisms of action, health benefits for the host, optimal production processes, screening methods, (meta)genomics, proteomics and metabolomics, host and bacterial physiology, application, and role in health and disease in man and animal. Beneficial Microbes is intended to serve the needs of researchers and professionals from the scientific community and industry, as well as those of policy makers and regulators. The journal will have five major sections: * Food, nutrition and health * Animal nutrition * Processing and application * Regulatory & safety aspects * Medical & health applications In these sections, topics dealt with by Beneficial Microbes include: * Worldwide safety and regulatory issues * Human and animal nutrition and health effects * Latest discoveries in mechanistic studies and screening methods to unravel mode of action * Host physiology related to allergy, inflammation, obesity, etc. * Trends in application of (meta)genomics, proteomics and metabolomics * New developments in how processing optimizes pro- & prebiotics for application * Bacterial physiology related to health benefits
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信